Chih-chiang Tsou is a director-level bioinformatics leader with over 18 years of experience translating computational proteomics and mass spectrometry research into production pipelines for chemical biology and HLA peptidomics. He has led and scaled informatics efforts through industry transitions—from Immatics discovery work to Scorpion Therapeutics’ acquisition by Eli Lilly and the subsequent Antares spin-out—demonstrating skill in building robust, acquisition-ready analytics infrastructure. With a Ph.D. in Bioinformatics and a strong CS/math foundation, he blends deep algorithmic insight with pragmatic software development to deliver reproducible discovery and clinical-grade workflows. Colleagues rely on him for end-to-end pipeline design, cross-functional translation of complex proteomics data, and rapid iteration under tight timelines. Notably, he repeatedly architects solutions that survive corporate M&A, preserving technical continuity while enabling rapid commercialization.
10 years of coding experience
18 years of employment as a software developer
Doctor of Philosophy (Ph.D.) Bioinformatics, Doctor of Philosophy (Ph.D.) Bioinformatics at University of Michigan
M.S. Computer Science and Information Management, M.S. Computer Science and Information Management at Providence University
Contributions:1 release, 2 pushes, 1 branch in 1 month
Find and Hire Top DevelopersWe’ve analyzed the programming source code of over 60 million software developers on GitHub and scored them by 50,000 skills. Sign-up on Prog,AI to search for software developers.